At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 29 enrolled
Drug / intervention
Erenumab Prefilled Syringe +1 moredrug
Likely dose
Erenumab Prefilled Syringe 140mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blinded, Single Site Study to Evaluate the Efficacy of Erenumab for Treatment of Idiosyncratic Facial Pain Mimicking Rhinosinusitis
In Brief
A Phase 4 clinical trial evaluating Erenumab Prefilled Syringe and Placebo for Facial Pain and Rhinosinusitis. Completed, enrolled 29 participants across 1 site.
Detailed Summary
This is a phase IV randomized, double-blinded, placebo-controlled study to evaluate the efficacy of Erenumab in subjects with midfacial pain or pressure, without clinical or radiographic evidence of sinusitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFacial Pain, Rhinosinusitis
CountriesUnited States
CollaboratorsAmgen
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartFeb 2021
Primary CompletionJul 2023
TodayJul 2026
First PostedJan 31, 2020
Enrollment StartFeb 10, 2021
Primary CompletionJul 11, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.4 years ago
Interventions
Erenumab Prefilled Syringedrug
140mg Erenumab, pre-filled syringe given by subcutaneous injection
Placeboother
Placebo, pre-filled syringe given by subcutaneous injection